![](https://partners4access.com/wp-content/uploads/2021/02/Blog-5-300x198.png)
Blogs
Will AIFA’s net price disclosure requirement be a game-changer for Orphan Drug access?
By Akshay Kumar, Partner & Andrea Bernardini, Analyst Email: [email protected] [email protected] In the latest guidelines for Pricing and Reimbursement (P&R) dossier submissions, Italian Medicines Agency